Prognostic factors in advanced renal cell cancer

Camillo Porta(University of Pavia), B. Rovereto, Mario Mensi, Chiara Paglino, Elisa Ferraris(Fondazione Salvatore Maugeri), Ilaria Imarisio(University of Pavia)

European Journal of Cancer Supplements

August 16, 2008

10.1016/j.ejcsup.2008.06.009

Cited by 1

Related Papers

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

|Journal of Hepatology|2012|821

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

|The Lancet Oncology|2012|550

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2012|275

Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy

|Radiotherapy and Oncology|2017|173

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

|Journal of Clinical Oncology|2024|170